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Summary
AIMS OF THE STUDY: Iron deficiency (ID) and iron defi-
ciency anaemia (IDA) are important conditions affecting a
large proportion of the general population, causing the pa-
tients physical and psychosomatic symptoms, particularly
fatigue, and significantly affecting their quality of life. Gen-
eral practitioners (GPs) are frequently consulted with non-
specific symptoms due to the ID. However, little evidence
is available to guide iron treatment. The aim of the Swiss
Delphi study was to generate a broad consensual Swiss
expert opinion in various therapeutic areas on diagnosis
and treatment of ID/IDA and their practical implications.
METHODS: Specific statements regarding clinical rele-
vance, practical diagnostic and therapeutic approaches,
and treatment were evaluated by Swiss experts in various
therapeutic areas using the Delphi method. “Consensus”
was defined as ≥80% agreement; the agreement of
50–79% was defined as “critical”, of <50% as “disagree-
ment”.
RESULTS: Consensus was reached for most statements.
In patients without systemic inflammation, the threshold of
30 μg/l provide a good accuracy for the diagnosis of ID
without anaemia. Ferritin levels within the range 30–50 μg/
l with TSAT <20% can indicate ID without anaemia. Iron
replacement therapy is accepted for treatment, not only
of IDA, but also of symptomatic ID without anaemia. GPs
play a central role in diagnosis and management of ID.
CONCLUSIONS: This consensus study provides potential
therapeutic strategies for management of iron deficiency
and is based on opinions of a high number of contributing
specialists, providing their views from a wide range of clin-
ical perspectives.
Key words: iron, anaemia, iron deficiency, iron replace-
ment therapy
Introduction
Iron deficiency (ID) and iron deficiency anaemia (IDA) are
important and prevalent conditions worldwide [1, 2]. ID
is the single frequent micronutrient deficiency in adults in
industrialised countries with the prevalence of up to 5%
[1, 3]. ID and IDA predict mortality [4] and are associated
with approximately 800,000 deaths per year [5].
Women of childbearing age are particularly at risk for ID,
as a result of monthly blood loss, pregnancy and deliv-
ery [6]. Moreover, many other conditions occur with ID
with or without anaemia as a major co-morbidity or con-
sequence, among them chronic heart failure [7, 8], chronic
kidney disease [9], cancer [10], inflammatory bowel dis-
eases [11, 12], and other chronic gastrointestinal and liver
disorders [6, 13]. ID has been associated with fatigue and
decreased functional capacity [14, 15], loss of productivity
[16], impaired quality of life [8]. ID treatment leads to im-
provement of fatigue [14, 15], and increases in endurance
and well-being [17, 18].
General practitioners (GPs) are often confronted with the
broad variety of signs and symptoms of ID and/or its un-
derlying illnesses [3], and are therefore primarily in charge
of its detection and diagnosis. However, the rather nonspe-
cific signs and symptoms of ID/IDA also occurr in other
conditions, which tends to make its differential diagnosis
difficult [6].
Existing guidelines on the diagnosis and treatment of ID/
IDA are mainly developed for specific therapeutic areas
and do not always provide practical recommendations for
GPs. Furthermore, there is a paucity regarding the treat-
ment of ID in the absence of anaemia in otherwise healthy
patients.
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Finally, GPs tend to refer to the analysis sheets they receive
from their trusted laboratory for diagnostic laboratory re-
sults, on which the serum ferritin ranges (the main diagnos-
tic parameter for ID), which are given as reference values,
are rather wide. Ferritin is a variable measurement because
of its active-phase character (e.g., falsely elevated values
in presence of inflammation), its value is thus sometimes
difficult to interpret and may not reflect the true iron status
in the body [6]. As a consequence, patients suffering from
ID may be missed and left untreated or can be over-treated.
Hence, indiscriminate use of iron replacement therapy and
other supplements has been reported [19, 20].
Therapeutic decisions can be challenging owing to lack of
or conflicting [21, 22] evidence from clinical trials.
To reduce such uncertainties and potential misuse of iron
replacement therapy, consensus methods have been devel-
oped to seek the opinion of a group of experts in order to
obtain an agreement on debated topics and to support the
decision-making process. The Delphi study technique is
such a method, which was developed to find the collective
expert opinion on a question without a clear answer in an
anonymous and structured manner. The Delphi study tech-
nique has been shown to be an appropriate method to elicit
consensus among a large number of participating experts
without the need for their face-to-face contact, to avoid
bias [23–25].
In this study, we report the results of a Swiss Delphi con-
sensus panel of experts in various therapeutic areas, organ-
ised to answer the debated questions regarding (a) the clin-
ical relevance, (b) the practical diagnostic and therapeutic
approaches, and (c) the treatment lead (if the specialist or
GP should be responsible for the iron replacement).
Methods
The Swiss Delphi study on iron deficiency aimed to elab-
orate practical recommendations on the diagnosis and the
treatment of ID and IDA. The Delphi methodology was
used to elaborate consensus-based recommendations. The
medical professional’s views were evaluated through ques-
tions regarding ID/IDA diagnosis and management.
Selection and formulation of statements
Selection of statements
The statements were selected and formulated by the ex-
perts of the different therapeutic areas (cardiologists,
nephrologists, gastroenterologists, gynaecologists, oncol-
ogists, and internists) in the first Delphi round and then
discussed and, if necessary, reformulated and re-evaluated.
For each therapeutic area, the choice of a particular publi-
cation as a source for a statement was based on a hierarchi-
cal approach as outlined in table 1.
Choice of sources for the statements
As the aim of the project was to elaborate a geographically
based consensus, the geographical approach from a local
(Swiss) to the international level was used with the as-
sumption that local guidelines and expert opinions adapt
the existing internationally recognised diagnostic and
treatment modalities according to local needs and the char-
acteristics of the local population. The top-down principle
assumed that a guideline presents a higher evidence level
than an expert opinion – points 1–5 in table 1. A Swiss
expert opinion was assumed to be more suitable for the
generation of a statement for Swiss physicians than a sin-
gle Swiss clinical trial, especially if the expert opinion was
based on one or more clinical trials – points 5 and 6 in
table 1. Finally, a meta-analysis presents a higher level of
evidence than a single clinical trial and an expert opinion,
both of which is deemed to present a lower level of evi-
dence: points 7–9 in table 1.
Literature search
The literature search was performed in March 2017. The
keywords “guideline”, “iron deficiency” and “anemia”
were used for each therapeutic area. Additionally, specific
keywords were used for the respective therapeutic area:
“chronic heart failure” in cardiology; “chronic kidney dis-
ease” and “chronic renal disease” in nephrology; “inflam-
matory bowel disease” in gastroenterology; “gynecology”,
“women in childbearing age”, “pregnancy” and “postpar-
tum” in gynaecology; “cancer” and “oncology” in oncolo-
gy; “geriatric” and “elderly” in internal medicine.
The selected articles had to cover the aspects of (a) clinical
consequences of iron deficiency according to the goals of
the current project and (b) the clinical research or expert
opinions on ID published by Swiss experts in various ther-
apeutic areas. The literature research was been performed
in:
1. Journals of (in order of precedence) Swiss, European,
or international societies of the respective therapeutic
area;
2. Internet sites of (in order of precedence) Swiss, Euro-
pean, or international societies of the respective thera-
peutic area;
3. PubMed;
4. Internet platforms on the topic of ID supported by
Swiss experts.
All publications, which resulted from the literature search,
and the statements, which resulted from the selected pub-
lications, were thoroughly reviewed, discussed and ap-
proved by the members of the Steering Committee and
Table 1: Choice of sources for the statements of the Swiss Delphi
study: hierarchical approach (in order of decreasing suitability).
1. Most recent guidelines elaborated by the Swiss society of the re-
spective therapeutic area
2. Most recent guidelines elaborated by the European society of
the respective therapeutic area
3. Most recent guidelines elaborated by the international society of
the respective therapeutic area
4. Most recent guidelines elaborated by the (a) American or (b) oth-
er national Societies of the respective therapeutic area
5. Expert opinion elaborated by Swiss Experts
6. Most recent randomised controlled trial by Swiss investigators
and / or with an iron preparation approved in Switzerland in the
respective therapeutic area
7. Most recent meta-analysis of randomised controlled trials in the
respective therapeutic area
8. Most recent randomised controlled in the respective therapeutic
area
9. Expert opinion elaborated by international experts in the respec-
tive therapeutic area
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the Expert Board, who were responsible for ensuring the
choice of the most relevant source.
Formulation of statements
The statements were formulated according to the following
principles:
1. The source of the highest level (table1) was considered
as basis for initial statement formulation.
2. If a guideline did not specify the diagnostic and/or
therapeutic approach, but referred to a clinical trial,
the diagnostic or therapeutic approach in this trial was
considered as the basis for statement formulation. In
this case, the study with the highest level of evidence
was considered as most relevant and first-line basis for
initial claim formulation.
3. If a guideline did not specify the clinical relevance
of ID and/or IDA in the respective therapeutic area,
the results of the most recent (in order of preference)
Swiss, European, American, or other study has been
considered as the most relevant and first-line basis for
initial statement formulation;
4. If a guideline or an expert opinion did not specify the
treatment lead ( the specialty of the physician who
should manage the patient), the initial statement has
been formulated as a recommendation for a consulta-
tion with a specialist in the respective therapeutic area.
The sources of statements are summarised in a supplemen-
tary list of references of statements (appendix 1). The ques-
tions were formulated to match as closely as possible the
respective source from literature. The formulation of the
questions was furthermore thoroughly revised and adapted
by experts in order to correspond to the medical language
used in Switzerland. The German and French translations
of the questions were tested in a specific round. Thus, a
good match of the questions with the respective literature
sources and also a good understanding of their sense by
Swiss physicians were ensured.
Recruitment of the expert panel
Selection of panel members
To be considered an expert within the respective therapeu-
tic area, each panellist had to fulfil the following criteria:
1. Approved by the Swiss Medical Association (FMH) as
medical specialist within the respective discipline;
2. More than 40% of their working time devoted to pa-
tient care;
3. At least five years of professional experience (in the
respective discipline);
4. Involved, depending on the specialist area, in the treat-
ment of a minimum of five patients suffering from iron
deficiency per year. This minimum number of five ID
patients was calculated as follows:
the estimated prevalence of ID/IDA in Switzerland
(~10% of Swiss population),
the number of Swiss residents (~8400000),
the number of Swiss physicians (~36000) and
the estimation that 20% of patients with ID/IDA visit a
physician during 1 year.
Distributing all these patients among all existing physi-
cians results in 4.6 patients with ID/IDA pro physician.
Thus, the number of five patients seemed reasonable as a
criterion determining practical experience in ID/IDA for a
Swiss physician.
The potential panel members were recruited after their in-
stitution had been selected, as described below. The head
physician of each institution in the respective therapeutic
area or the leading private practice clinician was contacted
by email or phone, informed about the study purposes and
asked to participate in the study. We did so because the
head physicians of the hospitals and leading private prac-
tice clinicians have years of experience and, as a result,
their clinical opinions are held in high esteem and, on oc-
casions, direct the practice of diagnosis and treatment [26].
If the physicians upon contact did not meet the recruitment
criteria or were not willing to participate, they were asked
to recommend an alternative physician within the same in-
stitution.
Participants were recruited over the course of 17 weeks in
February to June 2017. They received written information
about the project and instructions on how to fill out the
questionnaire.
Selection of medical institutions
In the Swiss nationwide medical registry all medical insti-
tutions are listed by location. This registry was used to re-
cruit physicians for each therapeutic area working in (a)
public and/or university hospitals, (b) private hospitals and
(c) medical (group) practices. All listed medical institu-
tions were randomly drawn from the list. If no panellist
could be recruited from an institution, another was ran-
domly drawn from the list. The random sampling proce-
dure for medical institutions was adopted separately for
each therapeutic area.
The proposed quota sampling with the minimal proportion
of physicians for each therapeutic area and the predefined
sample composition delineated by the language spoken are
outlined in table S1 (appendix 1).
Statement collection
The recruited panellists were invited via email to partici-
pate in an anonymous online survey. A reminder was send
after 1 week if the panellist had failed to respond to the
questionnaire. Participants who did not respond to the re-
minder were called and motivated to participate by the
study group.
Each statement could be rated on a five-point Likert scale:
strongly disagree (1), disagree (2), neither agree nor dis-
agree (3), agree (4), strongly agree (5), don’t know (99).
“Consensus” was defined as ≥80% agreement in the rating
of the single statements by the panellists; “critical consen-
sus” was defined as agreement of 50–79%, “disagreement”
was recorded if the agreement was <50%. Agreement was
if the panellists replied either “agree” or “strongly agree”
and disagreement if “disagree” or “strongly disagree”. The
panellists also had the possibility to comment on the state-
ments.
The Steering Committee had no contact with the panellists
and filled-in questionnaire was devoid of any personal
identifiers. The procedure for each panellist, displayed in
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the table S1 (appendix 1), was to fill out the general part
1, the specific part on the therapeutic area of the respective
panellist, and the general part 2.
Analysis
Percentages were calculated for consensus, critical consen-
sus and disagreement for each statement. Mean ± SD was
computed for the overall percentage of agreement, criti-
cal agreement and disagreement, respectively. Statistical
analyses were performed using SPSS/PC (version 22.0;
SPSS Inc., Chicago, IL, USA) software package.
Results
A total of 115 panellists were recruited within 99 institu-
tions. Of the 115 panellists, 93 from 80 institutions com-
pleted the survey, which corresponds to the return rate of
81% for panellists and 81% for institutions.
Over an eight-week period, the 93 panellists, 13 of whom
were cardiologists, 16 nephrologists, 14 gastroenterolo-
gists, 13 gynaecologists, 19 oncologists and 18 internists,
completed the survey. Twenty surveys were completed in
French, the rest in German. We performed only one con-
sensus round because the steering committee of the study
concluded that the results were already satisfactory after
the first round.
Overall, there were 440 statements. Consensus has been
achieved for 50% (n = 218), critical consensus for further
38% (n = 167) and disagreement for 12% (n = 54) of the
statements.
The proportion of agreement, critical agreement and dis-
agreement among the panellists of the respective thera-
peutic area is shown in table 2. The degree of agreement
regarding each statement is summarised in table S2 in ap-
pendix 1.
Diagnosis, clinical relevance and treatment of ID/IDA
All panellists of different therapeutic areas participated in
general parts 1 and 2 (table 2). Consensus was achieved on
the following statements (table S2, part A).
– To diagnose ID/IDA, serum ferritin with C-reactive
protein (CRP), haemoglobin, mean corpuscular volume
(MCV), mean corpuscular haemoglobin concentration
(MCHC) should be determined. However, ferritin can
be elevated in systemic inflammatory and liver dis-
eases, and thus is less reliable as a marker of iron stores
in those conditions. Low transferrin saturation (TSAT)
can be helpful indicating ID in such cases.
– The cause of ID needs to be elucidated before iron re-
placement therapy. The intravenous route should be
preferred if oral iron is not tolerated, is inefficient (e.g.,
the therapeutic dose fails to produce an increase in
haemoglobin of at least 1 g/l/day or of at least 20–30 g/
l after 3 weeks, after exclusion of folate and vitamin B12
deficiency), or bears risk of complications, or if a rapid
haemoglobin increase is needed, such as in the presence
of very low haemoglobin values during pregnancy and
postpartum or in the perioperative setting.
– To monitor treatment success, serum ferritin should be
measured 8–12 weeks after iron administration.
Critical consensus was achieved on the following state-
ments (table S2 , part A).
– ID without anaemia is clinically relevant in women of
childbearing age, elderly, individuals with chronic dis-
eases.
– ID can cause restless legs syndrome, exercise intoler-
ance, cognitive problems, alopecia, headache, koilony-
chias, Plummer-Vinson syndrome, frail nails, cheilosi-
tis and atrophic glossitis. Dyspnoea at rest and even
haemodynamic instability can occur in severe cases.
– In symptomatic ID patients with or without anaemia,
low ferritin is sufficient to confirm iron deficiency. A
serum ferritin level below 30 μg/l can be considered as
a cut-off to diagnose iron deficiency without anaemia in
the general population. Additionally, for ferritin levels
within the range of 30–50 μg/l, a TSAT <20% can indi-
cate ID without anaemia.
– However, TSAT can be increased by inflammation be-
cause transferrin is a negative acute-phase protein.
Measurement of serum soluble transferrin receptor
(sTr) concentrations and ferritin index (sTfR level / log
ferritin) can be helpful in estimating the need of iron re-
placement therapy in unclear situations, if no disease-
specific guidelines exist.
– Iron replacement therapy is indicated in symptomatic
ID patients without anaemia, with the oral route as the
treatment of choice. The intravenous can be used in cas-
es of low adherence.
– In symptomatic anaemic individuals (haemoglobin
<130 g/ for males and <120 g/l for females) with ID
(ferritin <30 μg/l) and without chronic diseases and in-
flammation, oral iron is the preferred therapeutic op-
tion.
– In anaemic individuals with chronic inflammation, oral
iron may not be sufficient as a therapeutic option if
baseline ferritin is <100 μg/l and TSAT <20%.
Table 2: Proportion of agreement, critical agreement and disagreement among the panellists.
Therapeutic area Number of statements Number of panel-
lists
Consensus
n (%)
Critical consensus
n (%)
Disagreement
n (%)
General part 1 109 93 48 (44) 43 (39) 18 (17)
Cardiology 42 13 29 (69) 13 (31) 0 (0)
Nephrology 43 16 33 (77) 7 (16) 3 (7)
Gastroenterology 42 14 18 (43) 15 (36) 9 (21)
Gynaecology 103 13 52 (50) 42 (41.3) 9 (8.7)
Oncology 60 19 21 (35) 30 (50) 9 (15)
Geriatrics 18 18 7 (39) 7 (39) 4 (22)
General part 2 23 93 11 (48) 10 (43.3) 2 (8.7)
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– In individuals with chronic disease(s), treatment of iron
deficiency can be based on higher ferritin-cut-offs, ac-
cording to the respective disease-specific guideline.
– Maintenance iron replacement therapy in order to avoid
re-occurrence of ID and IDA is desireable.
– There is a risk of overtreatment of ID without anaemia
in the Swiss healthcare system.
Diagnosis and treatment of iron deficiency in chronic
heart failure
Only cardiologists participated in this section (table 2).
Consensus was achieved on the following statements (table
S2 , part B).
– ID and IDA are common and relevant in chronic heart
failure and should be diagnosed on the basis of haemo-
globin, ferritin, CRP and TSAT measurement.
– Generally, if serum ferritin is <100 μg/l, or 100–300 μg/
l with concomitant TSAT <20%, ID without anaemia
can be diagnosed and treated intravenously according to
the treatment scheme used in the CONFIRM-HF trial
[27], with a subsequent ferritin check ideally 8–12
weeks after treatment, followed by annual measure-
ments of ferritin, TSAT and CRP.
– In compensated chronic heart failure, the responsibility
for ID and IDA treatment lies with the GP; decompen-
sated chronic heart failure the treatment responsibility
is with the cardiologist.
– Iron should be administered intravenously and discon-
tinued in the event of adverse reactions, signs of iron
toxicity or iron overload.
Critical consensus was achieved on the following state-
ments (table S2 , part B).
– IDA is associated with increased mortality.
– IDA in chronic heart failure, without further relevant
comorbidities such as chronic kidney disease, is defined
as haemoglobin levels <120 g/l in women and <130 g/l
in men, if ferritin is <100 μg/l, or 100–300 μg/l with
concomitant TSAT <20%.
– Oral iron may be ineffective in chronic heart failure.
Iron supplementation should be discontinued if TSAT is
>50% – a possible sign of iron overload.
Diagnosis and treatment of iron deficiency in chronic
kidney disease
Only nephrologists participated in this section (table 2).
Consensus was achieved on the following statements (table
S2 , part C).
– Anaemia is common in chronic kidney disease and pro-
gresses with progressing renal disease.
– Anaemia causes fatigue, and cognitive and depressive
disorders, and increases cardiovascular morbidity and
mortality.
– IDA is the most common and reversible cause of
anaemia in chronic kidney disease and is the main cause
of nonresponsiveness to erythropoiesis-stimulating
agents.
– Anaemia in chronic kidney disease is defined as haemo-
globin <135 g/l in males and <120 g/l in females. It
should be further evaluated if haemoglobin is <110 g/L
in either gender.
– ID in predialysis patients should be diagnosed and treat-
ed by the GP (in coordination with a nephrologist), and
in dialysis patients by the nephrologist.
– Oral iron is simple and cheap and does not require hos-
pital visits. However, it is poorly absorbed and associ-
ated with gastrointestinal side effects. Intravenous iron
is more effective in increasing haemoglobin, ferritin
and TSAT; however, it can cause hypersensitivity reac-
tions, under very rare circumstances. Thus, intravenous
iron can be considered as the preferred choice for IDA
in chronic kidney disease, ferritin should ideally be
checked 8–12 weeks after intravenous iron administra-
tion.
– For adults with chronic kidney disease and IDA, iron
replacement therapy should be started before erythro-
poiesis-stimulating agents if serum ferritin is <200 μg/l
and/or TSAT <25%. The TSAT limit of 45% should not
be exceeded.
Critical consensus has been achieved on the following
statements (table S2 , part C).
– Intravenous iron requires specialist clinic services and
there are theoretical concerns that individuals may be
exposed to increased oxidative stress and exacerbation
of infections.
– The serum ferritin limit of 500 μg/l should not be ex-
ceeded after iron replacement therapy.
Diagnosis and treatment of iron deficiency in inflam-
matory bowel disease
Only gastroenterologists participated in this section (table
2). Consensus was achieved on the following statements
(table S2 , part D).
– Anaemia is the most common systemic complication of
inflammatory bowel diseases and negatively influences
various aspects of the quality of life, such as physical
and emotional functioning, ability of work.
– Inflammatory bowel disease-associated anaemia can be
multifactorial – a combination of blood loss, decreased
iron absorption and anaemia of chronic disease.
– The current World Health Organization (WHO) defini-
tion of anaemia (haemoglobin <130 g/l in adult males
and <120 g/l in non-pregnant adult females) also ap-
plies to individuals with inflammatory bowel disease.
– All individuals with inflammatory bowel disease should
be assessed for the presence of anaemia.
– Diagnostic criteria for iron deficiency depend on the
level of inflammation.
– In individuals without clinical, endoscopic, or biochem-
ical evidence of inflammation, serum ferritin of <30 μg/
l is an appropriate criterion for ID; with inflammation,
serum ferritin <100 μg/l is appropriate.
– Iron replacement therapy can be considered when iron
deficiency without anaemia is present.
– Intravenous iron should be considered the preferred
treatment in clinically active inflammatory bowel dis-
ease and/or when the patient was previously intolerant
to oral iron and/or with haemoglobin <100 g/l, and fer-
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ritin should be checked ideally 8–12 weeks after treat-
ment (earlier testing could lead to falsely high values).
– Cessation and re-evaluation of the therapy is required in
the case of clinically relevant adverse reactions and/or
signs of iron toxicity or iron overload.
Critical consensus was achieved on the following state-
ments (table S2 , part D).
– Ferritin values of 30–50 μg/l and TSAT <20% indicate
ID.
– Iron replacement therapy is required in IDA, with the
goal of normalising haemoglobin and iron stores, which
are best achieved by early treatment initiation.
– The estimate of iron need should be based on baseline
haemoglobin and body weight. Intravenous iron should
be considered as the preferred treatment in Individuals
who need erythropoiesis-stimulating agents.
– Because of the frequent recurrence of IDA, individuals
with inflammatory bowel disease should be monitored
for recurrent ID every 3 months for at least a year after
correction, and every 6–12 months thereafter.
Iron deficiency in women of childbearing age including
pregnancy and postpartum
Only gynaecologists participated in this section (table 2).
Consensus has been achieved on the following statements
(table S2 , part E).
– ID and IDA are relevant, their treatment improves fa-
tigue, mental quality of life and physical performance.
– Oral iron is the preferred therapy in non-pregnant
women, but intravenous iron is indicated if oral iron is
not tolerated, bears risk of complications (e.g. in in-
flammatory bowel disease), or is not efficacious, that is,
fails to produce an increase of haemoglobin of at least 1
g/l/day or of at least 20–30 g/l after 3 weeks, after ex-
clusion of folate and vitamin B12 deficiency.
– ID is a frequent cause of anaemia during pregnancy and
can lead to an increased need for blood transfusions in
the event of major bleeding. It also can lead to fatigue,
reduced physical and mental performance, headache,
orthostatic dizziness.
– Anaemia is defined as a haemoglobin level of <110 g/l
in the first trimester, <105 g/l in the second and <110 g/
l in the third; ID is defined as ferritin <30 μg/l.
– ID in pregnancy can be treated by the GP, in coordina-
tion with the gynaecologist.
– In the first trimester, ID and mild IDA haemoglobin
90–105 g/l) should be treated with 80–200 mg oral iron
per day. In the second trimester, intravenous iron is in-
dicated in mild IDA (ferritin <30 μg/l and haemoglobin
90–105 g/l) and lack of response to oral iron (haemo-
globin increase less than 10 g/l within 14 days), lack of
adherence, or intolerance to oral iron, as well as in ad-
vanced anaemia (haemoglobin <90 g/l). In the third
trimester, intravenous iron can be considered as a means
of rapid iron replenishment.
– Postpartum anaemia is defined as haemoglobin <120 g/
l and is clinically relevant if haemoglobin is <100 g/l.
Six weeks after delivery, ferritin can be falsely elevated.
In mild postpartum anaemia (haemoglobin 95–120 g/l),
80–200 mg oral iron per day is indicated. Intravenous
iron should be considered if oral iron is not tolerated or
if the haemoglobin is as low as 70–95 g/l.
– The total dose of intravenous iron administered should
not exceed 1000 mg (or 20 mg/kg) per week.
– Serum ferritin should be checked, ideally 8–12
weeks after intravenous iron administration.
Critical consensus was achieved on the following state-
ments (table S2 , part E).
– For non-pregnant women of childbearing age, ID is di-
agnosed if ferritin is <30 μg/l, or 30–50 μg/l with con-
comitant TSAT of <20%; IDA is diagnosed if ,addition-
ally, haemoglobin is <110 g/l. If ferritin is <30 μg/l, the
probability that the iron stores are empty is 90%.
– ID should be treated if symptomatic.
– Oral iron is preferred for the treatment of IDA, but in-
travenous iron can be considered in the event of low ad-
herence.
– Anaemia is one of the most common problems in ob-
stetrics, occurring in more than one third of pregnant
women during the first half of pregnancy. It causes re-
duced lactation and bears a major risk for maternal and
foetal morbidity, such as preterm delivery, intrauterine
growth retardation and impaired placental develop-
ment.
– In the second trimester, intravenous iron can be consid-
ered as a means of rapid replenishment, for example in
patients belonging to the Jehovah’s Witnesses. In the
third trimester, intravenous iron therapy is indicated in
mild IDA (ferritin <30 μg/l and haemoglobin 90–105 g/
l) and insufficient response to oral iron (haemoglobin
increase by less than 10 g/l within 14 days), in Jeho-
vah’s Witnesses and in women with increased risk for
postpartum haemorrhage.
– The haemoglobin goal in pregnancy is >105 g/l. The
dose of ferric carboxymaltose can be estimated as fol-
lows:
– Total dose [mg] = body weight [kg] × (target Hb – cur-
rent Hb) [g/dl] × 2.4 + storage iron [mg].
– For this equation, the body weight before the beginning
of pregnancy, a target haemoglobin of 150 g/l and stor-
age iron of 500 mg for a body weight >35 kg or 15 mg/
kg for a body weight <35 kg should be considered.
– Postpartum, haemoglobin should be checked, depend-
ing on blood loss, the clinical condition, the prepartum
haemoglobin, the nadir of the postpartum haemoglobin
48 hours after delivery.
– The target postpartum haemoglobin is 110 g/l.
Diagnosis and treatment of iron deficiency in cancer
Only oncologists participated in this section (table 2). Con-
sensus was achieved on the following statements (table S2
, part F).
– In cancer patients, anaemia decreases physical fitness
and quality of life.
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– Ferritin may be elevated owing to malignancy, indepen-
dently of the iron stores, and is therefore not a reliable
marker of iron stores in cancer.
– -– Iron replacement therapy should be initiated as soon
as possible in symptomatic individuals with cancer and
ID.
– The therapy should be coordinated by all physicians,
but particularly by the oncologist.
– Intravenous iron is indicated in symptomatic patients
for a faster correction of iron deficiency.
– In individuals on erythropoiesis-stimulating agents,
who have symptomatic anaemia and TSAT of <50%, in-
travenous iron is indicated.
– Ferric carboxymaltose allows administration of high
iron doses in one infusion, enhancing individual com-
fort and reducing the number of visits to the clinic.
– Serum ferritin should be checked, ideally 8–12 weeks
after intravenous iron administration.
Critical consensus was achieved on the following state-
ments (table S2 , part F).
– There is a very high prevalence of functional and ab-
solute ID and IDA in individuals with cancer.
– Anaemia can lead to poorer performance and higher
mortality in cancer patients.
– Anaemia can be worsened by blunted endogenous ery-
thropoietin production in the kidney and reduced sensi-
tivity to erythropoietin.
– For ID diagnosis, the percentage of hypochromic red
cells (%HYPO), haemoglobin content of reticulocytes
(CHr), and ferritin index (sTfR/log ferritin) can be con-
sidered as helpful parameters in addition to ferritin and
TSAT.
– Oral iron is a valuable option for oligo symptomatic in-
dividuals with ID and cancer in remission without sys-
temic inflammation.
– Intravenous iron is indicated in symptomatic patients
with IDA and in patients with planned surgery at risk
for bleeding.
– In individuals with ferritin levels between 500 and 800
μg/l, iron replacement therapy should be based on indi-
vidual decisions.
– A loading dose of 1000 mg (not exceeding 20 mg/kg)
of ferric carboxymaltose will result in an adequate iron
supply.
– Following iron replacement therapy, TSAT should rise
more than 20–50%, ferritin by more than 100 μg/l and
CHr by more than 28 pg; sTfR and sTfR/log ferritin
should normalise.
– Iron replacement therapy should be discontinued if fer-
ritin increases to >800 μg/l.
Diagnosis and treatment of iron deficiency in elderly
individuals
Only geriatrists participated in this section (table 2). Con-
sensus was achieved on the following statements (table S2
, part G).
– In the elderly population (≥65 years old), anaemia has
important implications on quality of life, and ID is often
multifactorial, with causes including inadequate dietary
intake or absorption, occult bleeding and medication.
– Statements about diagnosis and treatment from the gen-
eral part 1 also apply to elderly individuals.
– In anaemic geriatric individuals, intravenous iron re-
placement therapy with ferric carboxymaltose can be
well tolerated.
– In elderly individuals with restless legs syndrome and
ID (defined as baseline ferritin <50 μg/l or TSAT
<16%), the administration of ferric carboxymaltose is
associated with a significant improvement of symp-
toms.
Critical consensus was achieved on the following state-
ments (table S2 , part G).
– ID is common in elderly and substantially contributes
to a high prevalence of anaemia observed in the last
decades of life, caused primarily by chronic inflamma-
tion and associated with mortality.
– The response to oral iron is often slow in elderly indi-
viduals.
– Iron therapy is efficacious if its therapeutic dose pro-
duces an increase of haemoglobin of at least 1 g/l/day
or of at least 2–3 g/l after 3 weeks.
Discussion
The contributions of experienced clinicians, based on their
daily practice, has helped overcome the lack of guidelines
based on randomised interventional studies. In this context,
the Delphi method represents one of the most reliable con-
sensus methods [24]. The Delphi method has been em-
ployed in order to achieve consensus in various diseases
[28–31]. So far, this is the first Delphi consensus with a
joint panel of experts that addressed the unmet needs in the
management of ID.
However, some study limitations merit consideration.
Firstly, the Delphi consensus is not a method to introduce
better evidence than that based on clinical trials; it repre-
sents a process to find a common clinical practise based on
a summary of experts’ opinions. Secondly, although more
than one consensus round is typically applied in Delphi
consensus [23], with an experts’ discussion before the next
round of voting process, in this study we performed only
one iteration of consensus building. We did so intentional-
ly, because a panel discussion before the next round could
lead to a group dynamic putting pressure on single individ-
uals to be compliant with the collective viewpoint. Thirdly,
some therapeutic area groups of specialists were relatively
small. The strength of our study is therefore that the state-
ments remained free of bias, individual and anonymous.
Furthermore, the results reported here are supported by a
high number of contributing specialists, who provided in-
formation on their views from a wide range of clinical per-
spectives.
Diagnosis of iron deficiency is complex and has been high-
ly debated in previous studies. Serum ferritin is a widely
accepted as the most effective indicator of ID. In patients
without systemic inflammation, the threshold of 30 μg/l
provided the highest product of sensitivity and specificity
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for the diagnosis of ID without anaemia, as shown in pre-
vious studies [6, 32] and as it is in line with the opinion of
Swiss experts in this report. However, the utility of ferritin
can be limited in patients with liver diseases, malignan-
cy or acute and chronic inflammation. In those conditions,
serum ferritin levels can be increased independently of the
iron load [6]. Additionally, as suggested by the experts, for
ferritin levels within the range of 30–50 μg/l, TSAT <20%
can indicate ID without anaemia. Although, the utility of
TSAT can also be limited because transferrin is a negative
acute phase protein, it can be a helpful tool and is recom-
mended in current guidelines for chronic diseases [11, 33,
34]. The combination of further laboratory parameters –
CRP, MCV, MCHC and sTfR and sTfR/log – with ferritin
and TSAT seem to provide the best assessment of ID [6].
Importantly, iron replacement therapy is accepted for treat-
ment not only of IDA [35], but also of symptomatic ID
without anaemia [15, 36]. As outlined above, either serum
ferritin <30 μg/l or ferritin 30–50 μg/l with TSAT <20%
can be used as a cut-off to initiate iron therapy. Intravenous
iron replacement can be considered if oral iron is not toler-
ated or not efficacious. Oral iron therapy can be regarded
as not efficacious if the therapeutic doses of iron fail to
produce an increase of haemoglobin of at least 20–30 g/l
after 3 weeks, as recommended in the respective Summa-
ry of Product Characteristics. However, the haemoglobin
increase can vary between different patients. Therefore, an
individual approach based on the expected Hb-increase in
the particular patient may be necessary.
According to the given statements, Swiss physicians show
a good adherence to a number of current EU Guidelines
[11, 34, 37–43] and to local Swiss recommendations [44].
The claims in the oncology part seem to be less well ac-
cepted. One possible explanation can be the reduced utility
of measuring ferritin in cancer patients: serum ferritin lev-
els are elevated in the most cancer patients and does not
reflect the iron stores [6]. A new guideline of the ESMO
is available now. In contrast, the claims in the cardiology
part seem to be best accepted: there was no disagreement
among the cardiology panellists. One possible explanation
could be that several randomised clinical trials on iron re-
placement therapy have been undertaken in Cardiology pa-
tients [17, 18, 45].
According to the Swiss Delphi study on iron deficiency,
GPs play a central role in the diagnosis and management
of ID, generally and in the particular therapeutic area. In
cardiology patients, the GP is responsible for treatment of
ID and IDA in compensated chronic heart failure, whereas
cardiologists take responsibility in decompensated chronic
heart failure. During pregnancy, the GP performs the am-
bulatory treatment of ID, in coordination with the gynae-
cologist. In patients with chronic kidney disease, the GP is
responsible for the diagnosis and treatment of ID in pre-
dialysis patients and the nephrologist takes that responsi-
bility in dialysis patients. We hope that the results sum-
marised in this study help to support GPs in their daily
practice by giving them guidance on how best to diagnose
and treat patients suffering from ID.
Conclusions
This consensus study provides potential therapeutic strate-
gies for the management of ID and the results reported
here are reflective of a substantial number of respondents
(physicians) covering a wide range of specialities.
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